our team
Our Team
We believe that success comes from bringing together the right people. Our team combines the deep scientific expertise of our co-founders and scientific discoverers with a network of highly experienced drug developers. This team possesses the skills needed to address every facet of the drug development process, from innovation to the clinic and to market authorization to ultimately benefit patients.
Team Members
Dr. Thomas Boehm
Thomas Boehm, MD. is scientific founder of Daocrates Bio and works at the Department of
Clinical Pharmacology at the Medical University of Vienna (MUV).
Thomas Boehm, MD. is scientific founder of Daocrates Bio and works at the Department of Clinical Pharmacology at the Medical University of Vienna (MUV). He studied medicine in Vienna and received his doctorate under Helmut Sinzinger at the MUV.
During his studies, Thomas worked at the Institute of Physiology of the MUV with Bernd Binder on vascular cell biology issues. From 1993 to 1996 he was a post-doc with Kim Nasmyth at the Research Institute of Molecular Pathology (IMP) in Vienna, studying the cell cycle in yeast. After post-doctoral work at Harvard Medical School with Judah Folkman in Boston and working as Medical Director at Jerini AG in Berlin (2004-2008) and as Clinical Development Manager at Bavarian Nordic AG, AFFiRiS AG & Intercell AG, he returned to the MUV.
Thomas has written three non-fiction books: Cancer Lives on Blood Alone, The Resistance Trap, and The Manipulated Evolution: How Our Society Changes the Genetic Code. The affinity for evolution arose from the confrontation with cancer, viruses and bacteria, which have perfected Darwinian selection processes, not always for the benefit of humans.
Thomas obtained his MD degree from the MUV and has an MBA from INSEAD (2000).
Prof. Dr. Bernd Jilma
Prof. Bernd Jilma, MD. is scientific founder of Daocrates Bio and is a specialist in internal medicine and clinical pharmacology.
Prof. Bernd Jilma, MD. is scientific founder of Daocrates Bio and is a specialist in internal medicine and clinical pharmacology. He has a long-standing interest in mechanistic and clinical pharmacology studies with anticoagulants and antiplatelet drugs and has established a human endotoxin as well as a histamine challenge model at his institution.
Additionally, he has served in various functions at the European Medicines Agency providing scientific advice related to new drugs in development. Efficient clinical trial design is one of his many current interests. Major contributions in the Orphan Drugs Sector include the design of phase I-III trials that have led to the marketing authorization applications of caplacizumab in thrombotic thrombocytopenic purpura and sutimlimab for cold agglutinin disease. His contributions to the scientific field have been published in the most prestigious as well as other high-impact journals.
Thomas Boehm, who joined his research group, developed a recombinant diamine oxidase, which, as a “pan-antihistamine”, can for the first time prevent its effect on all four receptors at the same time through the rapid metabolism of histamine. Bernd’s further research will also focus on the treatment of mast cell activation syndromes (mastocytosis, urticaria, asthma, anaphylaxis, etc.).
Read Bio
Peter Greaney, PhD.
Peter Greaney, PhD. is a global deal-maker and is passionate about advancing innovative
science for the benefit of patients.
Peter Greaney, PhD. is a global deal-maker and is passionate about advancing innovative science for the benefit of patients.
Peter has international experience in building successful biotech companies. He has been responsible for the successful execution of numerous business development deals in his career and has experience in a wide array of deal structures. He is experienced in seeking new business opportunities, leading negotiations, and managing research collaborations.
At ADC Therapeutics, Peter was the Head of Corporate Development and played an integral role transforming the company from a private R&D biotech to a NYSE listed public biotech with a commercial therapeutic product. Prior to ADC Therapeutics, Peter held medical and business positions of increasing responsibility at Celgene in Switzerland and the United States. He held roles in Business Development, Strategy & Operations, Market Research & Business Intelligence, Medical Affairs, and Medical Development.
Prior to Celgene, Peter was a Preclinical Senior Scientist at Apoxis, S.A. in Switzerland and an intern scientist at Servier, Paris.
Peter graduated with a Bachelor of Science in Cell Biology from the University of East Anglia and a PhD in Molecular and Cellular Biology from the University of Nottingham (supported by Servier).
Read Bio
Kevin Lynch, MB, BS.
Kevin Lynch, MB, BS. is inspired by the opportunity to develop transformative medicines for patients.
Kevin Lynch, MB, BS. is inspired by the opportunity to develop transformative medicines for patients.
He has lived and worked in Australia, Asia, UK, and Switzerland, operating in both small, start-up environments as well as large, multi-nationals.
Kevin was Chief Medical Expert during Antengene’s formative years and then through a period of extreme growth as Chief Medical Officer. He supervised their broad clinical program with Xpovio (Selinexor) in Asia-Pacific, as well as an extensive first-in-human early development program.
During over 11 years at Celgene Kevin was closely involved in the successful clinical development and registration of Revlimid (lenalidomide), Pomalyst (pomalidomide), Vidaza (azacitidine), Onureg (oral azacitidine) and Idhifa (enasidinib).
During his 10 years with Novartis, as one of the inaugural Oncology Medical Directors for the company, he played a key role in the development and approvals of multiple transformative drugs including Glivec (imatinib), Tasigna (nilotinib), Zometa (zoledronic acid), Femara (letrozole) and Exjade (deferasirox).
Kevin graduated B Med Sci and MB, BS from the University of Tasmania in Australia. His post-graduate training in Pharmaceutical Medicine was completed in the UK, where he gained his Fellowship of the Faculty of Pharmaceutical Medicine.
Read Bio
Gertjan Bartlema
Gertjan Bartlema, thrives on building teams and creating collaborative impact. He is a pragmatic and authentic leader with broad operational biotech experience.
Gertjan Bartlema, thrives on building teams and creating collaborative impact. He is a pragmatic and authentic leader with broad operational biotech experience.
Gertjan was the CEO of VICO Therapeutics BV a privately held Netherlands based company focused on antisense oligonucleotide-based RNA modulating therapeutics for rare CNS diseases.
During his 20+ years global biotech career he was part of emerging organizations and new capability building, including healthcare big data/real-world data and marketing & sales excellence capabilities. During his 12 years at Celgene (US and Switzerland), he was part of the European management team, the corporate business development team that acquired Abraxis and the information knowledge utilization team that established an industry leading network of real-world data and technology partnerships including COTA, Inc., Flatiron Health, and GNS Healthcare and strategic partnerships with IBM Watson, Health2047, and M2Gen.
Other roles he held during his career include Strategy, Marketing & Sales Excellence, Business Planning and Financial Planning & Analysis. He started his biotech career at Amgen Europe based in Lucerne, Switzerland. Over a nine-year period at Amgen he was based in Thousand Oaks, CA and Switzerland.
Gertjan holds a Masters in Economics from Maastricht University, the Netherlands and was an ERASMUS student at Bern University, Switzerland. He holds dual Dutch and Swiss citizenship. He lives with his family in Switzerland.
Read Bio